臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52844409 線上人數 : 663 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"mok t"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 31-40 / 52 (共6頁)
<< < 1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2020-05-26T09:26:40Z	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: Analysis of LUX-Lung 3 and 6	Chih-Hsin Yang;Kim M;Massey D;Gibson N;Hirsh V;O'Byrne K;Yamamoto N;Mok T;Schuler M;Hou M;Li W;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Hu C.-P; Feng J; Lu S; Huang Y; Li W; Hou M; Schuler M; Mok T; Yamamoto N; O'Byrne K; Hirsh V; Gibson N; Massey D; Kim M; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:39Z	Checkpoint Inhibitors in Metastatic EGFR-Mutated Non?�Small Cell Lung Cancer?�A Meta-Analysis	Chih-Hsin Yang;Mok T;Gebski V;Links M;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Links M; Gebski V; Mok T; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:33Z	A Review of Regimens Combining Pemetrexed With an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in the Treatment of Advanced Nonsquamous Non?�Small-Cell Lung Cancer	Park K.;Puri T;Orlando M;Han B;Mok T;Chih-Hsin Yang; CHIH-HSIN YANG; Mok T; Han B; Orlando M; Puri T; Park K.
臺大學術典藏	2020-05-26T09:26:32Z	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6)	O?�Byrne K; Geater S.L; Zhou C; Massey D; Märten A; Lungershausen J; CHIH-HSIN YANG; Schuler M; Mok T; Yamamoto N; Huang Y; Lu S; Hu C.-P; Feng J; Sequist L.V; Hirsh V; Wu Y.-L; Chih-Hsin Yang;Lungershausen J;M?rten A;Massey D;Zhou C;Geater S.L;O??Byrne K;Yamamoto N;Mok T;Schuler M;Huang Y;Lu S;Feng J;Hu C.-P;Sequist L.V;Hirsh V;Wu Y.-L
臺大學術典藏	2020-05-26T09:26:31Z	Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: A systematic review and meta-analysis	Chih-Hsin Yang;Mok T;Gralla R.J;Herbst R.S;Gebski V;Links M;Cooper W;Lord S;Man J;Lee C.K; Lee C.K; Man J; Lord S; Cooper W; Links M; Gebski V; Herbst R.S; Gralla R.J; Mok T; CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:28Z	The Value of Early Depth of Response in Predicting Long-Term Outcome in EGFR-Mutant Lung Cancer	Chih-Hsin Chih-Hsin Yang;Mok T;Gralla R;Gebski V;Davies L;Asher R;Mitsudomi T;Fukuoka M;Rosell R;Sequist L;Wu Y.L;Marschner I;Lord S;Lee C.K; Lee C.K; Lord S; Marschner I; Wu Y.L; Sequist L; Rosell R; Fukuoka M; Mitsudomi T; Asher R; Davies L; Gebski V; Gralla R; Mok T; Chih-Hsin CHIH-HSIN YANG
臺大學術典藏	2020-05-26T09:26:27Z	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials	Park K.;Paz-Ares L; Chih-Hsin Yang;M?rten A;Peil B;Mok T;Boyer M;O'Byrne K;Yamamoto N;Hirsh V;Schuler M;Barrios C.H;Kato T;Tsai C.-M;Lee K.H;Zhang L;Orlov S;Geater S.L;Tan E.-H;Sequist L.V;Wu Y.-L; Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG; Paz-Ares L; Park K.
臺大學術典藏	2020-05-26T09:26:21Z	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer	Park K;Bennouna J;Boyer M;Hida T;Hirsh V;Kato T;Lu S;Mok T;Nakagawa K;O'Byrne K;Paz-Ares L;Schuler M;Sibilot D.M;Tan E.-H;Tanaka H;Wu Y.-L;Chih-Hsin Yang;Zhang L;Zhou C;M?rten A;Tang W;Yamamoto N.; Park K; Bennouna J; Boyer M; Hida T; Hirsh V; Kato T; Lu S; Mok T; Nakagawa K; O'Byrne K; Paz-Ares L; Schuler M; Sibilot D.M; Tan E.-H; Tanaka H; Wu Y.-L; CHIH-HSIN YANG; Zhang L; Zhou C; Märten A; Tang W; Yamamoto N.
臺大學術典藏	2020-05-26T09:26:20Z	First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression	Schuler M;Tan E.-H;O??Byrne K;Zhang L;Boyer M;Mok T;Hirsh V;Chih-Hsin Yang;Lee K.H;Lu S;Shi Y;Kim S.-W;Laskin J;Kim D.-W;Arvis C.D;K?lbeck K;Massey D;M?rten A;Paz-Ares L;Park K.; Schuler M; Tan E.-H; O?�Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K.
臺大學術典藏	2020-05-26T09:26:19Z	Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer	Woodford R;Loh Y;Lee J;Cooper W;Marschner I;Lewis C.R;Millward M;Lord S;Gralla R.J;Chih-Hsin Yang;Mok T;Lee C.K.; Woodford R; Loh Y; Lee J; Cooper W; Marschner I; Lewis C.R; Millward M; Lord S; Gralla R.J; CHIH-HSIN YANG; Mok T; Lee C.K.

顯示項目 31-40 / 52 (共6頁)
<< < 1 2 3 4 5 6 > >>
每頁顯示[10|25|50]項目